ArticleNature medicine2026
Global breast cancer survival estimates in 2017-2021 to advance the WHO Global Breast Cancer Initiative.
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global breast cancer survival estimates in 2017-2021 to advance the WHO Global Breast Cancer Initiative.Nature medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) Global Breast Cancer Initiative aims to attain meaningful global breast cancer mortality reductions by 2040-a target that hinges on improvements in patient outcomes and survival. So far, however, data on cancer survival remain limited in low- and middle-income countries. The WHO estimated population-based age-standardized 5-year net survival for women diagnosed with breast cancer between 2017 and 2021 across all 194 Member States, providing a global benchmark for monitoring breast cancer outcomes. Here we found that median 5-year net survival varied widely across WHO regions during 2017-2021: 39.1% (95% uncertainty interval 34.1-44.7%) in the African Region, 61.0% (51.4-69.8%) in the Eastern Mediterranean Region, 66.3% (57.7-73.7%) in the South-East Asia Region, 81.1% (78.6-83.5%) in the Western Pacific Region, 84.0% (82.8-85.1%) in the European Region and 88.5% (86.7-90.1%) in the Region of the Americas. Persisting disparities in survival reflect profound global inequities; sustained initiatives to narrow gaps in access to diagnosis and treatment for breast cancer are crucial to strengthening health systems. This will enable all countries to ensure optimal outcomes for their patients with breast cancer and achieve Global Breast Cancer Initiative and Sustainable Development Goals targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.